GCR The Guide to Life Sciences: An Economist’s Perspective on Abuse of Dominance and Killer Acquisitions in the Pharma Industry
1 minute read
![](https://compass-lexecon.transforms.svdcdn.com/production/editorial/2024/08/GCR-Guide-to-Life-Sciences-3-feature.jpg?auto=format&fit=crop&crop=focalpoint&q=82&w=1280&h=720&fp-x=0.5&fp-y=0.5&dm=1724229375&s=210d74355ecb8ed28922960e18850307)
Share
Expert economists Valerie Meunier, Rameet Sangha and David Sevy authored a chapter for Global Competition Review's third edition of The Guide to Life Sciences.
This article was originally published by GCR here. The views expressed are those of the authors only and do not necessarily represent the views of Compass Lexecon, its management, its subsidiaries, its affiliates, its employees, or clients.
Introduction
This chapter addresses the following competition issues, from an economics perspective, as they relate to the pharmaceutical industry:
- exploitative abuse of a dominant position through excessive pricing; and
- excluding actual or potential/nascent competitors via:
- rebates and discounts; and
- killer acquisitions.
Read the full chapter here
Meunier, V., Sangha, R., and Sevy, D. (2024): An Economist’s Perspective on Exploitative Abuse of Dominant Position and Excluding Competitors Through Killer Acquisitions. The Guide to Life Sciences, Third Edition.